Lakeshore Financial Planning Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 12,343 shares of the biopharmaceutical company's stock, valued at approximately $327,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the fourth quarter worth $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the fourth quarter valued at $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer in the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Insider Transactions at Pfizer
In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.06% of the company's stock.
Analyst Ratings Changes
A number of research firms recently commented on PFE. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.
Check Out Our Latest Stock Analysis on PFE
Pfizer Trading Down 0.6 %
Shares of NYSE:PFE traded down $0.15 during mid-day trading on Monday, reaching $26.13. 37,863,216 shares of the company's stock were exchanged, compared to its average volume of 36,651,219. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm has a market capitalization of $148.21 billion, a price-to-earnings ratio of 18.53, a PEG ratio of 0.64 and a beta of 0.61. The business's fifty day moving average price is $26.15 and its 200-day moving average price is $27.02.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. The company's quarterly revenue was up 24.7% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
